Novellia: $18M Series A Targets Pharma's $50B Real-World Data Problem

NEW YORK, Tuesday, June 9, 2026 — Novellia, the New York–based real-world data startup, announced an $18 million Series A led by Spark Capital on June 2, 2026, with Khosla Ventures, Acrew Capital, Bling Capital and TMV joining the round. The financing brings total funding for the New York–based real-world data startup to $28 million. Novellia is also launching a patient-facing mobile app that extends its existing online platform, letting individuals pull together up to 20 years of medical records in roughly 30 seconds and choose whether to share anonymized data with pharmaceutical researchers.

The pitch to investors: the $50 billion real-world data industry built on insurance claims and hospital exports is broken, and the patient is the missing source of truth.

Key Takeaways

• Novellia raised $18M Series A at a moment when Q1 2026 digital health funding hit $4.0B across 110 deals, with 59% concentrated in just 12 mega-rounds.
• The company says it already counts several top-10 pharma companies as customers on seven-figure, multi-year contracts, with Daiichi Sankyo and AstraZeneca publicly confirmed.
• Novellia's platform currently has roughly 30,000 users and has processed about 35 million health records, according to MM+M — a small footprint with what the company describes as high-signal data.
• Spark Capital General Partner Alex Finkelstein led the round; TMV partner Emma Silverman cited a willingness-versus-infrastructure gap among patients.
• The deal lands as the broader market splits into "haves and have-nots," with mega-rounds capturing investor attention while early-stage rounds tighten.

Context & Analysis

Patient-consented data is moving from theory to category. Novellia's model collects records directly from patients via APIs unlocked by U.S. interoperability rules, then runs proprietary NLP on the unstructured layer — physician notes, lab narratives, diagnostic reports — that traditional claims vendors strip out. CEO Shashi Shankar, a former Genentech real-world evidence operator, told MedCity News that traditional vendors "can't actually stitch together a single complete patient story."

The investor thesis is structural. Spark's Alex Finkelstein said pharma data is "too old, too slow, and too disconnected from patients," while TMV partner Emma Silverman said in the funding announcement that nearly 70% of patients are open to contributing data for medical breakthroughs, conditional on control, transparency and privacy safeguards. Novellia's interview with MM+M surfaced concrete outputs: GLP-1 cohort analysis suggesting patients with higher comorbidity burden respond better to weight-loss therapy and stay on longer, and a triglyceride decimal-point error caught by cross-referencing raw lab data against physician notes.

Related: How Health Tech Scales in 2026, Led by Siemens Healthineers and Gartner

Competitive Landscape

Novellia is entering a real-world data market dominated by claims-and-EHR aggregators — companies like IQVIA, Veeva and Komodo Health — whose datasets pharma R&D leaders increasingly find incomplete. The competitive question is whether a patient-consented network can scale fast enough to threaten institutional incumbents whose data flows are locked into payer and provider contracts.

The wider funding backdrop favors scale. Rock Health data shows the average Q1 deal size climbed to $36.7 million, the highest tracked since 2021, with 12 mega-deals capturing nearly 60% of capital. eMarketer's read: capital is concentrating among established names, signaling fundraising friction for early-stage companies. Novellia's $18M Series A is smaller than the headline rounds but lands in an investment thesis adjacent to OpenEvidence and Verily — high-signal data infrastructure pharma will pay for.

For deeper context, see our Health Tech analysis: "Why Health Systems Are Scaling Digital Care in 2026, According to McKinsey and Gartner".

For deeper context, see our related analysis: "Garner Health: $100M Series E Lifts Valuation to $2.74B".

What It Means

For Enterprise Buyers

Pharma R&D and medical affairs teams that, according to Shankar in MedCity News, spend $80–100 million per year on real-world data now have a credible patient-consented alternative. The procurement question shifts from "does this dataset exist?" to "is it complete and consented?" Novellia's NLP on unstructured notes is the differentiator buyers should probe in diligence, alongside coverage of priority therapeutic areas — GLP-1s, cardiometabolic, rare disease — that Shankar told MobiHealthNews are commercial priorities.

Additional coverage: How Health Tech Is Rewiring Clinical Operations in 2026, According to Gartner and Deloitte

For Investors

The Series A validates a sub-category but does not yet prove it. With ~30,000 users, Novellia is a thesis bet on patient ownership rules accelerating record portability. Comparable late-stage health data plays — Verily's $300M round and Whoop's reported $10.1B valuation, according to Rock Health — show where the multiples sit if Novellia executes. Risk: incumbent RWD vendors copy the patient-consented layer faster than Novellia scales its network.

Additional coverage: Common Health Tech AI Vendor Selection Criteria That Drive Value in 2026.

Related: What Health Tech Buyers Want in 2026, According to Microsoft, Google and Gartner

Forward Outlook

Watch three milestones over the next 12 months. First, Novellia's mobile app rollout — patient acquisition is the network's binding constraint. Second, expansion of seven-figure contracts beyond the publicly named Daiichi Sankyo and AstraZeneca relationships flagged by MM+M. Third, the CMS Health Technology Ecosystem and Interoperability Framework noted by MobiHealthNews — federal data-liquidity policy is the regulatory tailwind that determines whether patient-consented platforms become primary infrastructure or a niche layer.

Related: Preparing Health Tech AI Architectures for Scalable Care Delivery in 2026.

For deeper context, see our related analysis: "Top Health Tech Startups and Companies in 2026".

Sources include company disclosures, regulatory filings, analyst reports, and industry briefings.

Related Coverage

• More Health Tech Analysis
• Latest Technology News

Analysis based on company announcements, investor disclosures, regulatory filings, Reuters, Bloomberg, Financial Times, CNBC, SEC documentation, and publicly available market data as of publication.